查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591802

肝炎检测解决方案/诊断市场：按疾病类型、技术和最终用户划分 - 全球预测 2025-2030 年

Hepatitis Test Solution/Diagnosis Market by Disease Type, Technology, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

肝炎检测解决方案/诊断市场2023年估值为35.3亿美元，预计到2024年将达到37.1亿美元，复合年增长率为5.48%，到2030年将达到51.3亿美元。

在肝炎检测解决方案和诊断领域，市场范围包括旨在检测和管理不同类型肝炎感染（甲型、乙型、丙型、丁型、戊型）的各种产品和技术。这些解决方案的需求很大程度上是由于药物使用增加、不安全输血和无保护性行为等因素导致肝炎发病率上升。应用范围涵盖医院、诊断实验室和研究组织，最终用户包括医疗保健提供者、公共卫生组织和个别患者。

主要市场统计
基准年[2023] 35.3亿美元
预测年份 [2024] 37.1亿美元
预测年份 [2030] 51.3亿美元
复合年增长率（%） 5.48%

由于诊断测试技术的进步，包括采用 PCR、免疫测量和就地检验，提高了诊断的准确性和速度，该市场正在经历显着增长。特别是在新兴市场，政府提高意识和筛检的努力正在对成长产生重大影响。此外，不断增长的医疗保健支出和不断增长的早期检测需求正在为市场进入者创造潜在机会。然而，市场面临一些限制，例如与先进测试解决方案相关的高成本、意识有限（尤其是在新兴市场）以及严格的法规结构抑制了市场的快速渗透。

潜在的创新领域包括开发低成本快速检测套组、携带式诊断设备以及改进的基于人工智慧的资料分析，以提供更好的预测见解和患者管理平台。这些进步有可能大大促进资源有限环境中的广泛获取和实施。市场竞争激烈，主要企业不断进步并结盟，推出更强大的诊断工具。企业应专注于加强研发能力，与技术创新者形成策略联盟，打造差异化产品。我们还可以透过肝炎预防和检测的宣导活动来开拓开拓的市场，从而扩大我们的市场覆盖范围并推动成长。

市场动态：揭示快速发展的肝炎检测解决方案/诊断市场的关键市场洞察

供需的动态交互作用正在改变肝炎检测解决方案/诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球肝炎盛行率上升
    • 疾病早期发现与诊断的必要性
    • 提高政府和非营利组织对肝炎的认识
  • 市场限制因素
    • 检测和诊断肝炎的费用高昂
  • 市场机会
    • 病毒性肝炎检测与诊断的进展
    • 就地检验选项简介
  • 市场挑战
    • 与不准确的测试结果相关的担忧

波特五力：引领肝炎检测解决方案/诊断市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肝炎检测解决方案/诊断市场的外部影响

外部宏观环境因素在塑造肝炎检测解决方案/诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肝炎检测解决方案/诊断市场的竞争状况

肝炎检测解决方案/诊断市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵肝炎检测解决方案/诊断市场供应商的绩效评估

FPNV 定位矩阵是评估肝炎检测解决方案/诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，描绘肝炎检测解决方案/诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对肝炎检测解决方案/诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的肝炎发生率正在上升
      • 疾病早期发现与诊断的必要性
      • 政府和非营利组织意识提升
    • 抑制因素
      • 检测和诊断肝炎的费用高昂
    • 机会
      • 病毒性肝炎检测与诊断的进展
      • 就地检验选项简介
    • 任务
      • 与不准确的测试结果相关的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肝炎检测解决方案/诊断市场：依疾病类型

  • 甲型肝炎
  • B型肝炎
  • C型肝炎

第七章肝炎检测解决方案/诊断市场：依技术分类

  • 酵素免疫分析法
  • 恒温核酸增幅技术
  • 聚合酵素链锁反应
  • 快速诊断测试

第 8 章 肝炎检测解决方案/诊断市场：依最终使用者分类

  • 血库
  • 诊断实验室
  • 医院

第九章北美和南美的肝炎检测解决方案/诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区肝炎检测解决方案/诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的肝炎检测解决方案/诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 赛诺菲宣布在英国推出 AVAXIM Junior，作为 12 个月至 15 岁儿童甲型肝炎病毒感染的主动免疫治疗
    • UnitAid 投资 3,100 万美元减少伤害工作，以预防注射毒品者和高风险族群中的C型肝炎
    • 卫生署与当地实验室合作扩大可治癒丙型肝炎的检测
    • 罗氏推出双抗体/抗原丙型C型肝炎病毒诊断测试
    • 雅培推出检测B型肝炎病毒的解决方案
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Avantor Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • Cepheid
  • Creative Diagnostics
  • DiaSorin SpA
  • Epitope Diagnostics, Inc.
  • Everlywell, Inc.
  • F. Hoffmann-La Roche AG
  • FUJIREBIO Inc.
  • GenMark Diagnostics, Inc.
  • Grifols SA
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • MedMira Inc.
  • Merck & Co., Inc
  • Meridian Bioscience, Inc.
  • OraSure Technologies, Inc.
  • Ortho Clinical Diagnostics
  • Prometheus Laboratories
  • QIAGEN GmbH
  • Quest Diagnostics Incorporated
  • Randox Laboratories
  • Sanofi SA
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics
  • Werfen, SA
Product Code: MRR-43127F727883

The Hepatitis Test Solution/Diagnosis Market was valued at USD 3.53 billion in 2023, expected to reach USD 3.71 billion in 2024, and is projected to grow at a CAGR of 5.48%, to USD 5.13 billion by 2030.

In the arena of Hepatitis Test Solutions and Diagnostics, the market scope encompasses a range of products and technologies designed to detect and manage different types of hepatitis infections (A, B, C, D, E). The necessity of these solutions is largely propelled by rising incidences of hepatitis due to factors like increased drug use, unsafe blood transfusions, and unprotected sex. Their application spans across hospitals, diagnostic laboratories, and research institutes, with end-users including healthcare providers, public health organizations, and individual patients.

KEY MARKET STATISTICS
Base Year [2023] USD 3.53 billion
Estimated Year [2024] USD 3.71 billion
Forecast Year [2030] USD 5.13 billion
CAGR (%) 5.48%

The market is witnessing substantial growth due to technological advancements in diagnostic testing, such as the adoption of PCR, Immunoassays, and point-of-care testing, which enhance the accuracy and speed of diagnosis. Government initiatives to increase awareness and screening, especially in emerging markets, are significantly influencing growth. Additionally, increasing healthcare expenditures and the rising demand for early detection are creating potential opportunities for market players. However, the market faces limitations such as high costs associated with advanced testing solutions, limited awareness, especially in developing regions, and stringent regulatory frameworks that can impede rapid market penetration.

Potential areas of innovation include the development of low-cost, rapid testing kits, portable diagnostic devices, and improvement in AI-based data analytics to provide better predictive insights and patient management platforms. These advances could greatly facilitate wider access and implementation in resource-limited settings. The nature of the market is highly competitive with continuous advancements and collaborations among key players to introduce more robust diagnostic tools. Companies should focus on strengthening their R&D capabilities and forming strategic alliances with technological innovators to create differentiated products. Exploring untapped markets through educational initiatives about hepatitis prevention and testing can also increase market reach and facilitate growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hepatitis Test Solution/Diagnosis Market

The Hepatitis Test Solution/Diagnosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of hepatitis worldwide
    • Need for earlier detection and diagnosis of diseases
    • Increasing awareness about hepatitis by government and non-profit organizations
  • Market Restraints
    • High cost associated with tests and diagnosis of hepatitis
  • Market Opportunities
    • Advances in viral hepatitis testing and diagnosis
    • Introduction of point-of-care testing options
  • Market Challenges
    • Concerns associated with inaccurate test results

Porter's Five Forces: A Strategic Tool for Navigating the Hepatitis Test Solution/Diagnosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hepatitis Test Solution/Diagnosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hepatitis Test Solution/Diagnosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hepatitis Test Solution/Diagnosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hepatitis Test Solution/Diagnosis Market

A detailed market share analysis in the Hepatitis Test Solution/Diagnosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hepatitis Test Solution/Diagnosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hepatitis Test Solution/Diagnosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hepatitis Test Solution/Diagnosis Market

A strategic analysis of the Hepatitis Test Solution/Diagnosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hepatitis Test Solution/Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Avantor Inc., Beckman Coulter, Inc., Bio-Rad Laboratories Inc., bioMerieux SA, Cepheid, Creative Diagnostics, DiaSorin S.p.A., Epitope Diagnostics, Inc., Everlywell, Inc., F. Hoffmann-La Roche AG, FUJIREBIO Inc., GenMark Diagnostics, Inc., Grifols S.A., Hologic, Inc., Laboratory Corporation of America Holdings, MedMira Inc., Merck & Co., Inc, Meridian Bioscience, Inc., OraSure Technologies, Inc., Ortho Clinical Diagnostics, Prometheus Laboratories, QIAGEN GmbH, Quest Diagnostics Incorporated, Randox Laboratories, Sanofi S.A., Siemens AG, Thermo Fisher Scientific Inc., Vela Diagnostics, and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Hepatitis Test Solution/Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Hepatitis A, Hepatitis B, and Hepatitis C.
  • Based on Technology, market is studied across Enzyme-Linked Immunosorbent Assay, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, and Rapid Diagnostic Tests.
  • Based on End-User, market is studied across Blood Banks, Diagnostic Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of hepatitis worldwide
      • 5.1.1.2. Need for earlier detection and diagnosis of diseases
      • 5.1.1.3. Increasing awareness about hepatitis by government and non-profit organizations
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with tests and diagnosis of hepatitis
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in viral hepatitis testing and diagnosis
      • 5.1.3.2. Introduction of point-of-care testing options
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with inaccurate test results
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hepatitis Test Solution/Diagnosis Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Hepatitis A
  • 6.3. Hepatitis B
  • 6.4. Hepatitis C

7. Hepatitis Test Solution/Diagnosis Market, by Technology

  • 7.1. Introduction
  • 7.2. Enzyme-Linked Immunosorbent Assay
  • 7.3. Isothermal Nucleic Acid Amplification Technology
  • 7.4. Polymerase Chain Reaction
  • 7.5. Rapid Diagnostic Tests

8. Hepatitis Test Solution/Diagnosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Blood Banks
  • 8.3. Diagnostic Laboratories
  • 8.4. Hospitals

9. Americas Hepatitis Test Solution/Diagnosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hepatitis Test Solution/Diagnosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hepatitis Test Solution/Diagnosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Sanofi Announces Launch of AVAXIM Junior in the UK for Active Immunization Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years
    • 12.3.2. Unitaid Makes USD 31 Million Investment in Harm Reduction Efforts to Prevent Hepatitis C Among People who Inject Drugs and Others at High Risk
    • 12.3.3. DOH Partners with Local Laboratories to Expand Testing for Curable Hepatitis C
    • 12.3.4. Roche Launches Dual Antibody, Antigen Hepatitis C Virus Diagnostic Test
    • 12.3.5. Abbott launches solution to detect Hepatitis B virus
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Avantor Inc.
  • 4. Beckman Coulter, Inc.
  • 5. Bio-Rad Laboratories Inc.
  • 6. bioMerieux SA
  • 7. Cepheid
  • 8. Creative Diagnostics
  • 9. DiaSorin S.p.A.
  • 10. Epitope Diagnostics, Inc.
  • 11. Everlywell, Inc.
  • 12. F. Hoffmann-La Roche AG
  • 13. FUJIREBIO Inc.
  • 14. GenMark Diagnostics, Inc.
  • 15. Grifols S.A.
  • 16. Hologic, Inc.
  • 17. Laboratory Corporation of America Holdings
  • 18. MedMira Inc.
  • 19. Merck & Co., Inc
  • 20. Meridian Bioscience, Inc.
  • 21. OraSure Technologies, Inc.
  • 22. Ortho Clinical Diagnostics
  • 23. Prometheus Laboratories
  • 24. QIAGEN GmbH
  • 25. Quest Diagnostics Incorporated
  • 26. Randox Laboratories
  • 27. Sanofi S.A.
  • 28. Siemens AG
  • 29. Thermo Fisher Scientific Inc.
  • 30. Vela Diagnostics
  • 31. Werfen, S.A.

LIST OF FIGURES

  • FIGURE 1. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023